Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2007 1
2008 1
2010 1
2011 1
2012 1
2013 1
2015 1
2016 1
2017 1
2018 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Manual lymphatic drainage for lymphedema following breast cancer treatment.
Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, Bao T, Bily L, Tuppo CM, Williams AF, Karadibak D. Ezzo J, et al. Cochrane Database Syst Rev. 2015 May 21;(5):CD003475. doi: 10.1002/14651858.CD003475.pub2. Cochrane Database Syst Rev. 2015. PMID: 25994425 Free PMC article. Review.
BACKGROUND: More than one in five patients who undergo treatment for breast cancer will develop breast cancer-related lymphedema (BCRL). BCRL can occur as a result of breast cancer surgery and/or radiation therapy. BCRL can …
BACKGROUND: More than one in five patients who undergo treatment for breast cancer will develop breast cancer
Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes.
Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K. Han E, et al. Ann Surg Oncol. 2011 Apr;18(4):912-6. doi: 10.1245/s10434-010-1487-0. Epub 2011 Jan 12. Ann Surg Oncol. 2011. PMID: 21225354
Clinicians frequently encounter patients who reject standard treatment, but data on outcomes of patients choosing CAM as primary treatment for breast cancer are also lacking. ...CONCLUSIONS: Alternative therapies used as …
Clinicians frequently encounter patients who reject standard treatment, but data on outcomes of patients choosing CAM as pr
Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial.
Heudel PE, Van Praagh-Doreau I, Duvert B, Cauvin I, Hardy-Bessard AC, Jacquin JP, Stefani L, Vincent L, Dramais D, Guastalla JP, Blanc E, Belleville A, Lavergne E, Pérol D. Heudel PE, et al. Support Care Cancer. 2019 May;27(5):1879-1889. doi: 10.1007/s00520-018-4449-x. Epub 2018 Sep 7. Support Care Cancer. 2019. PMID: 30194492 Clinical Trial.
PURPOSE: Endocrine therapy (ET) used to reduce the risk of recurrence in hormone receptor-expressing disease (75% of breast cancers) is associated with worsening of climacteric symptoms with a negative impact on quality of life (QoL). ...CONCLUSIONS: T …
PURPOSE: Endocrine therapy (ET) used to reduce the risk of recurrence in hormone receptor-expressing disease (75% of breast ca …
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA; CISNET-BOLD Collaborative Group. Jayasekera J, et al. J Natl Cancer Inst. 2018 Dec 1;110(12):1360-1369. doi: 10.1093/jnci/djy059. J Natl Cancer Inst. 2018. PMID: 29718314 Free PMC article.
BACKGROUND: We used two models to simulate a proposed noninferiority trial of radiotherapy (RT) omission in low-risk invasive breast cancer to illustrate how modeling could be used to predict the trial's outcomes, inform trial design, and contribute to …
BACKGROUND: We used two models to simulate a proposed noninferiority trial of radiotherapy (RT) omission in low-risk invasive breast
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T, Balkenende EME, Beerendonk CCM, Fleischer K, Stoop D, Bos AME, Lambalk CB, Schats R, van Golde RJT, Schipper I, Louwé LA, Cantineau AEP, Smeenk JMJ, de Bruin JP, Reddy N, Kopeika Y, van der Veen F, van Wely M, Linn SC, Goddijn M. Dahhan T, et al. Contemp Clin Trials. 2017 Oct;61:96-100. doi: 10.1016/j.cct.2017.07.009. Epub 2017 Jul 11. Contemp Clin Trials. 2017. PMID: 28710053 Clinical Trial.
BACKGROUND: Chemotherapy for breast cancer may have a negative impact on reproductive function due to gonadotoxicity. Fertility preservation via banking of oocytes or embryos after ovarian stimulation with FSH can increase the likelihood of a future li …
BACKGROUND: Chemotherapy for breast cancer may have a negative impact on reproductive function due to gonadotoxi …
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA. Colditz GA. Crit Rev Food Sci Nutr. 2010;50 Suppl 1(s1):10-2. doi: 10.1080/10408398.2010.526838. Crit Rev Food Sci Nutr. 2010. PMID: 21132580 Free PMC article.
Such an analysis does not evaluate the exposure-disease relationship, but rather examines the impact of offering a new therapy versus an alternative therapy (regardless of adherence to the intervention, or control or placebo). ...Compliance or adherenc …
Such an analysis does not evaluate the exposure-disease relationship, but rather examines the impact of offering a new therapy
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS. Tan DS, et al. Breast Cancer Res Treat. 2008 Sep;111(1):27-44. doi: 10.1007/s10549-007-9756-8. Epub 2007 Oct 6. Breast Cancer Res Treat. 2008. PMID: 17922188
BACKGROUND: We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer pati …
BACKGROUND: We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of tr …
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y. Hida AI, et al. Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3. Breast Cancer Res Treat. 2016. PMID: 27260189 Free PMC article.
Tumor-infiltrating lymphocytes (TILs) have potential value for stratifying the treatment of breast cancer (BC), though their precise use remains unclear. ...TILs after primary systemic therapy may be useful for the further stratification of t
Tumor-infiltrating lymphocytes (TILs) have potential value for stratifying the treatment of breast cancer (BC), though …
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis.
Greco M, Agresti R, Cascinelli N, Casalini P, Giovanazzi R, Maucione A, Tomasic G, Ferraris C, Ammatuna M, Pilotti S, Menard S. Greco M, et al. Ann Surg. 2000 Jul;232(1):1-7. doi: 10.1097/00000658-200007000-00001. Ann Surg. 2000. PMID: 10862188 Free PMC article.
OBJECTIVE: To evaluate the impact of breast carcinoma (T1-2N0) surgery without axillary dissection on axillary and distant relapses, and to evaluate the usefulness of a panel of pathobiologic parameters determined from the primary tumor, independent of axilla …
OBJECTIVE: To evaluate the impact of breast carcinoma (T1-2N0) surgery without axillary dissection on axillary and distant rel …
Omission of surgery in elderly patients with early stage breast cancer.
Hamaker ME, Bastiaannet E, Evers D, Water Wv, Smorenburg CH, Maartense E, Zeilemaker AM, Liefers GJ, Geest Lv, de Rooij SE, van Munster BC, Portielje JE. Hamaker ME, et al. Eur J Cancer. 2013 Feb;49(3):545-52. doi: 10.1016/j.ejca.2012.08.010. Epub 2012 Sep 6. Eur J Cancer. 2013. PMID: 22959185
AIM: To assess national trends over time in surgery for elderly patients with resectable breast cancer (BC) and to evaluate clinical outcome and cause of death after the omission of surgery in a regional cohort of elderly patients. ...Although this may appear …
AIM: To assess national trends over time in surgery for elderly patients with resectable breast cancer (BC) and to evaluate cl …
11 results
Jump to page
Feedback